Clinical Trial: NCT02343120
Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies
Status:
COMPLETEDPhase:
Phase 1| Lead Sponsor: | BeiGene |
| Information Provided By: | BeiGene |
| Last Update Posted: | 2022-04-28 |
Study Overview
Brief Summary
This study evaluated the safety, tolerability, pharmacokinetic profile and efficacy of BGB-3111 in participants with B-cell lymphoid malignancies.
Official Title
A Phase I/II, Open-Label, Multiple-Dose, Dose Escalation and Expansion Study to Investigate the Safety and Pharmacokinetics of the BTK Inhibitor BGB-3111 in Subjects With B-Cell Lymphoid Malignancies
Conditions
B-cell Malignancies
Intervention / Treatment
- Drug: Zanubrutinib
Other Study ID Numbers
- BGB-3111-AU-003
- 2016-003364-39
- 2016
Start Date (Actual)
2014-09-04
Primary Completion Date (Actual)
2021-03-31
Study Completion Date (Actual)
2021-03-31
Enrollment (Actual)
385
Study Type
Interventional
Phase
Phase 1, Phase 2
| Lead Sponsor: | BeiGene |
| Information Provided By: | BeiGene |
| Last Update Posted: | 2022-04-28 |
Study Overview
Brief Summary
This study evaluated the safety, tolerability, pharmacokinetic profile and efficacy of BGB-3111 in participants with B-cell lymphoid malignancies.
Official Title
A Phase I/II, Open-Label, Multiple-Dose, Dose Escalation and Expansion Study to Investigate the Safety and Pharmacokinetics of the BTK Inhibitor BGB-3111 in Subjects With B-Cell Lymphoid Malignancies
Conditions
B-cell Malignancies
Intervention / Treatment
- Drug: Zanubrutinib
Other Study ID Numbers
- BGB-3111-AU-003
- 2016-003364-39
- 2016
Start Date (Actual)
2014-09-04
Primary Completion Date (Actual)
2021-03-31
Study Completion Date (Actual)
2021-03-31
Enrollment (Actual)
385
Study Type
Interventional
Phase
Phase 1, Phase 2